0001193125-23-168524.txt : 20230616 0001193125-23-168524.hdr.sgml : 20230616 20230616085201 ACCESSION NUMBER: 0001193125-23-168524 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230616 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Prometheus Biosciences, Inc. CENTRAL INDEX KEY: 0001718852 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 814282653 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40187 FILM NUMBER: 231019440 BUSINESS ADDRESS: STREET 1: 3050 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 422-4300 MAIL ADDRESS: STREET 1: 3050 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Precision IBD, Inc. DATE OF NAME CHANGE: 20171004 8-K 1 d466468d8k.htm 8-K 8-K
false 0001718852 --12-31 0001718852 2023-06-16 2023-06-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2023

 

 

PROMETHEUS BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-40187   81-4282653

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3050 Science Park Road
San Diego, CA
  92121
(Address of Principal Executive Offices)   (Zip Code)

(858) 422-4300

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   RXDX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.01

Completion of Acquisition or Disposition of Assets.

On June 16, 2023 (the “Closing Date”), Prometheus Biosciences, Inc., a Delaware corporation (“Prometheus”), completed the previously announced merger of Splash Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Merck & Co., Inc., a New Jersey corporation (“Merck”), with and into Prometheus (the “Merger”), with Prometheus surviving the Merger as a wholly owned subsidiary of Merck. The Merger was effectuated pursuant to the Agreement and Plan of Merger, dated as of April 15, 2023 (the “Merger Agreement”), by and among Merck, Merger Sub and Prometheus, as previously disclosed by Prometheus on April 17, 2023 in a Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”).

Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each of the issued and outstanding shares of Prometheus common stock, par value $0.0001 per share (“Prometheus Common Stock”), other than any shares of Prometheus Common Stock (i) owned immediately prior to the Effective Time by Merck, Merger Sub or Prometheus or by any direct or indirect wholly owned subsidiary of Merck, Merger Sub or Prometheus or (ii) owned by Prometheus stockholders who are entitled to demand and have properly and validly demanded their appraisal rights under Delaware law, was canceled and extinguished and automatically converted into the right to receive $200.00 per share in cash (the “Merger Consideration”), without interest and subject to any applicable withholding taxes.

In addition, at the Effective Time, (i) each outstanding Prometheus stock option, whether vested or unvested, was automatically canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (A) the number of shares of Prometheus Common Stock underlying such option immediately prior to the Effective Time multiplied by (B) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, (ii) each outstanding Prometheus restricted stock unit (“RSU”) was automatically canceled and converted into the right to receive an amount in cash equal to the product of (A) the number of shares of Prometheus Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (B) the Merger Consideration, without interest and subject to any applicable withholding taxes, and (iii) each outstanding share of restricted stock of Prometheus automatically became fully vested and was converted into the right to receive the Merger Consideration.

Prometheus’ definitive proxy statement, filed with the SEC on May 16, 2023, as supplemented on June 6, 2023 (the “Proxy Statement”), contains additional information about the Merger and the Merger Agreement, including information concerning the interests of directors, executive officers and affiliates of Prometheus in the Merger.

The foregoing description of the Merger Agreement contained in this Item 2.01 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement. A copy of the Merger Agreement was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by Prometheus with the SEC on April 17, 2023, and is incorporated by reference into this Item 2.01.

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

In connection with the consummation of the Merger, Prometheus requested that The NASDAQ Stock Market LLC (“NASDAQ”) suspend trading of Prometheus Common Stock prior to the opening of trading on June 16, 2023 and file with the SEC an application on Form 25 to delist and deregister Prometheus Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The delisting of Prometheus Common Stock from NASDAQ will be effective 10 days after the filing of the Form 25. Following the effectiveness of such Form 25, Prometheus


intends to file with the SEC a certification on Form 15 requesting the termination of registration of the Prometheus Common Stock under Section 12(g) of the Exchange Act and the suspension of Prometheus’ reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to Prometheus Common Stock.

The information set forth in Item 2.01 of this report is incorporated by reference into this Item 3.01.

 

Item 3.03

Material Modification to Rights of Security Holders.

The information set forth in Items 2.01, 3.01 and 5.03, respectively, of this report is incorporated by reference into this Item 3.03.

 

Item 5.01

Changes in Control of Registrant.

As a result of the consummation of the Merger, a change of control of Prometheus occurred on the Closing Date and Prometheus became a wholly owned subsidiary of Merck. Merck funded the acquisition through the use of cash on hand, commercial paper or existing or new credit facilities, as described in the Proxy Statement.

The information set forth in Items 2.01, 3.03, 5.02 and 5.03, respectively, of this report is incorporated by reference into this Item 5.01.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The information set forth in Item 2.01 is incorporated by reference into this Item 5.02.

Pursuant to the Merger Agreement, as of the Effective Time, each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus. At the Effective Time, Jon Filderman, Rita Karachun and Aaron Rosenberg, each a director of Merger Sub immediately prior to the Effective Time, became directors of Prometheus.

In connection with the Merger, at the Effective Time, Mark C. McKenna, Keith W. Marshall, Ph.D. and Mark Stenhouse ceased to be executive officers of Prometheus. In accordance with the terms of the Merger Agreement, at the Effective Time, the officers of Merger Sub became the officers of Prometheus.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The information set forth in Item 2.01 is incorporated by reference into this Item 5.03.

Pursuant to the Merger Agreement, as of the Effective Time, the certificate of incorporation of Prometheus, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “Amended and Restated Certificate of Incorporation”). The Amended and Restated Certificate of Incorporation is filed as Exhibit 3.1 hereto and incorporated by reference into this Item 5.03.

In addition, as of the Effective Time, in accordance with the Merger Agreement, the bylaws of Prometheus, as in effect immediately prior to the Effective Time, were amended and restated in their entirety (the “Bylaws”). The Bylaws, as so amended and restated, are filed as Exhibit 3.2 hereto and incorporated by reference into this Item 5.03.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

   Description
2.1    Agreement and Plan of Merger, dated as of April 15, 2023, by and among Prometheus Biosciences, Inc., Merck & Co., Inc. and Splash Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Prometheus’ Current Report on Form 8-K filed on April 17, 2023)*
3.1    Amended and Restated Certificate of Incorporation of Prometheus Biosciences, Inc.
3.2    Amended and Restated Bylaws of Prometheus Biosciences, Inc.
104    Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document

 

*

Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Prometheus hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that Prometheus may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits or schedules so furnished.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 16, 2023   PROMETHEUS BIOSCIENCES, INC.
    By:  

/s/ Kelly E.W. Grez

    Name:   Kelly E.W. Grez
    Title:   Secretary
EX-3.1 2 d466468dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

PROMETHEUS BIOSCIENCES, INC.

FIRST: The name of the corporation is Prometheus Biosciences, Inc. (hereinafter, the “Corporation”).

SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of its registered agent at such address is The Corporation Trust Company.

THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (“DGCL”).

FOURTH: The total number of shares of stock which the Corporation shall have authority to issue is 1,000 shares of common stock, par value $0.001 per share.

FIFTH: The business and affairs of the Corporation shall be managed by or under the direction of the board of directors, and the directors need not be elected by ballot unless required by the Bylaws of the Corporation.

SIXTH: In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the board of directors is expressly authorized to make, amend or repeal the bylaws or adopt new bylaws without any action on the part of the stockholders of the Corporation; provided that any bylaw adopted or amended by the board of directors, and any powers thereby conferred, may be amended, altered or repealed by the stockholders of the Corporation.

SEVENTH: Except to the extent that DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the Corporation for or with respect to any acts or omissions of such director occurring prior to such amendment or repeal. If DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by DGCL as so amended.

EIGHTH: The Corporation reserves the right to amend and repeal any provision contained in this Certificate of Incorporation in the manner from time to time as


prescribed by the laws of the State of Delaware. All rights herein conferred are granted subject to this reservation.

NINTH. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee, agent or stockholder of the Corporation to the Corporation or the Corporation’s stockholders, creditors or other constituents, (c) any action asserting a claim arising pursuant to any provision of DGCL or this Certificate of Incorporation or the Bylaws of the Corporation, or (d) any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein; provided that, the provisions of this Article NINTH will not apply to suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended, the Securities and Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Corporation, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. To the fullest extent permitted by applicable law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article NINTH. Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article NINTH. If any provision or provisions of this Article NINTH shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article NINTH (including, without limitation, each portion of any sentence of this Article NINTH containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.

EX-3.2 3 d466468dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

AMENDED AND RESTATED

BYLAWS

OF

PROMETHEUS BIOSCIENCES, INC.

ARTICLE I

STOCKHOLDERS

Section 1. Annual Meeting.

An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors (the “Board of Directors”) of Prometheus Biosciences, Inc. (the “Corporation”) shall each year fix, which date shall be within 13 months of the last annual meeting of stockholders or, if no such meeting has been held, the date of incorporation.

Section 2. Special Meetings.

Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors or the president and shall be held at such place, on such date, and at such time as they or he or she shall fix.

Section 3. Notice of Meetings.

Notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, shall be given, not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as otherwise provided herein or required by law (meaning, here and hereinafter, as required from time to time by the Delaware General Corporation Law or the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”)).

When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than 30 days after the date for which the meeting was originally noticed, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, shall


be given to each stockholder in conformity herewith. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and, except as otherwise required by law, shall not be more than 60 nor less than 10 days before the date of such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.

Section 4. Quorum.

At any meeting of the stockholders, the holders of a majority of all of the shares of the stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law. Where a separate vote by a class or classes or series is required, a majority of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. A quorum once established, shall not be broken by the subsequent withdrawal of enough votes to leave less than a quorum.

If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time. At any such adjourned meeting at which there is a quorum, any business may be transacted that might have been transacted at the meeting originally called.

Section 5. Organization.

Such person as the Board of Directors may have designated or, in the absence of such a person, the President of the Corporation or, in his or her absence, such person as may be chosen by the holders of a majority of the shares entitled to vote who are present, in person or by proxy, shall call to order any meeting of the stockholders and act as chairman of the meeting. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.

Section 6. Conduct of Business.

The chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seem to him or her in order. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting.

Section 7. Proxies and Voting.

At any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting. Any copy, facsimile, email or

 

2


other reliable reproduction of the writing or transmission created pursuant to this paragraph may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile, email or other reproduction shall be a complete reproduction of the entire original writing or transmission.

The Corporation may, and to the extent required by law, shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman of the meeting.

All elections shall be determined by a plurality of the votes cast, and except as otherwise required by law, all other matters shall be determined by a majority of the votes cast affirmatively or negatively.

Section 8. Stock List.

The officer who has charge of the stock ledger of the Corporation shall, at least 10 days before every meeting of stockholders, prepare and make a complete list of stockholders entitled to vote at any meeting of stockholders, provided, however, if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date, arranged in alphabetical order and showing the address of each such stockholder and the number of shares registered in his or her name. Such list shall be open to the examination of any stockholder for a period of at least 10 days prior to the meeting in the manner provided by law.

A stock list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law. This list shall presumptively determine (a) the identity of the stockholders entitled to examine such stock list and to vote at the meeting and (b) the number of shares held by each of them.

Section 9. Consent of Stockholders in Lieu of Meeting.

Any action required to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the

 

3


Corporation’s registered office shall be made by hand or by certified or registered mail, return receipt requested.

Every written consent shall bear the date of signature of each stockholder who signs the consent and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered to the Corporation, a written consent or consents signed by a sufficient number of holders to take action are delivered to the Corporation in the manner prescribed in the first paragraph of this Section. A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written, signed and dated for the purposes of this Section to the extent permitted by law. Any such consent shall be delivered in accordance with Section 228(d)(1) of the Delaware General Corporation Law.

Any copy, facsimile, email or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile, email or other reproduction shall be a complete reproduction of the entire original writing.

ARTICLE II

BOARD OF DIRECTORS

Section 1. General Powers.

The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. The Board of Directors may adopt such rules and procedures, not inconsistent with the Certificate of Incorporation, these Bylaws, or applicable law, as it may deem proper for the conduct of its meetings and the management of the Corporation.

Section 2. Number and Term of Office.

The number of directors who shall constitute the whole Board of Directors shall be such number as the Board of Directors shall from time to time have designated, provided that the size of the initial Board of Directors shall be equal to the number of directors elected by the Incorporator of the Corporation. Each director shall be elected for a term of one year and until his or her successor is elected and qualified, except as otherwise provided herein or required by law.

Whenever the authorized number of directors is increased between annual meetings of the stockholders, a majority of the directors then in office shall have the power to elect such new directors for the balance of a term and until their successors are elected and qualified. Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office unless, at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease.

Section 3. Vacancies.

If the office of any director becomes vacant by reason of death, resignation, disqualification, removal or other cause, a majority of the directors remaining in office, although

 

4


less than a quorum, may elect a successor for the unexpired term and until his or her successor is elected and qualified.

Section 4. Regular Meetings.

Regular meetings of the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have been established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.

Section 5. Special Meetings.

Special meetings of the Board of Directors may be called by one-third of the directors then in office (rounded up to the nearest whole number) or by the President and shall be held at such place, on such date, and at such time as they or he or she shall fix. Notice of the place, date, and time of each such special meeting shall be given to each director by whom it is not waived by mailing written notice not less than five days before the meeting or by facsimile, email or other electronic transmission of the same not less than 24 hours before the meeting. Unless otherwise indicated in the notice thereof, any and all business may be transacted at a special meeting.

Section 6. Quorum.

At any meeting of the Board of Directors, a majority of the total number of the whole Board of Directors shall constitute a quorum for all purposes. If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date, or time, without further notice or waiver thereof.

Section 7. Participation in Meetings By Conference Telephone.

Members of the Board of Directors, or of any committee thereof, may participate in a meeting of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other and such participation shall constitute presence in person at such meeting.

Section 8. Conduct of Business.

At any meeting of the Board of Directors, business shall be transacted in such order and manner as the Board of Directors may from time to time determine, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein or required by law. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

5


Section 9. Compensation of Directors.

Directors, as such, may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors, including, without limitation, their services as members of committees of the Board of Directors.

Section 10. Action Without Meeting.

Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all directors or members of such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writings or electronic transmissions are filed with the minutes of proceedings of the Board of Directors or committee in accordance with applicable law.

Section 11. Resignation.

Any director may resign at any time by notice given in writing or by electronic transmission to the Corporation. Such resignation shall take effect at the date of receipt of such notice by the Corporation or at such later time as is therein specified.

Section 12. Removal.

Except as prohibited by applicable law or the Certificate of Incorporation, the stockholders entitled to vote in an election of directors may remove any director from office at any time, with or without cause, by the affirmative vote of a majority in voting power thereof.

ARTICLE III

COMMITTEES

Section 1. Committees of the Board of Directors.

The Board of Directors may from time to time designate committees of the Board of Directors, with such lawfully delegable powers and duties as it thereby confers, to serve at the pleasure of the Board of Directors and shall, for those committees and any others provided for herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternate members who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of any member of any committee and any alternate member in his or her place, the member or members of the committee present at the meeting and not disqualified from voting, whether or not he or she or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member.

Section 2. Conduct of Business.

Each committee may determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein or required by law. Adequate provision shall be made for notice to members of all meetings; one-third of the

 

6


members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of the proceedings of such committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

ARTICLE IV

OFFICERS

Section 1. Generally.

The officers of the Corporation shall be elected annually by the Board of Directors and shall include a president, a treasurer, one or more vice presidents, and a secretary. The Board of Directors, in its discretion, may also elect one or more vice presidents, assistant treasurers, assistant secretaries, and other officers. Any two or more offices may be held by the same person. Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal.

Section 2. President.

The president shall have general supervision over the business of the Corporation and other duties incident to the office of president, and any other duties as may be from time to time assigned to the president by the Board of Directors and subject to the control of the Board of Directors in each case. He or she shall have power to sign all stock certificates, contracts and other instruments of the Corporation which are authorized and shall have general supervision and direction of all of the other officers, employees and agents of the Corporation.

Section 3. Vice President.

Each vice president shall have such powers and duties as may be delegated to him or her by the Board of Directors or the president. One vice president shall be designated by the Board of Directors to perform the duties and exercise the powers of the President in the event of the President’s absence or disability.

Section 4. Treasurer.

The Treasurer shall have the responsibility for maintaining the financial records of the Corporation. He or she shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions and of the financial condition of the Corporation. The Treasurer shall also perform such other duties as the Board of Directors may from time to time prescribe.

Section 5. Secretary.

The Secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the stockholders and the Board of Directors. He or she shall have charge of the

 

7


corporate books and shall perform such other duties as the Board of Directors may from time to time prescribe.

Section 6. Delegation of Authority.

In case any officer is absent, or for any other reason that the Board of Directors may deem sufficient, the president or the Board of Directors may delegate for the time being the powers or duties of such officer to any other officer or to any director.

Section 7. Removal.

Any officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors.

Section 8. Action with Respect to Securities of Other Entities.

Unless otherwise directed by the Board of Directors, the President or any officer of the Corporation authorized by the President shall have power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of stockholders (or comparable holders of equity interests) of or with respect to any action of stockholders (or comparable holders of equity interests) of any other corporation or other entity in which this Corporation may hold securities and otherwise to exercise any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation or other entity.

ARTICLE V

STOCK

Section 1. Certificates of Stock.

Shares of stock of the Corporation may, but need not be, represented by certificates. Each holder of stock represented by certificates shall be entitled to a certificate signed by, or in the name of the Corporation by, any two authorized officers of the Corporation, including the President or a Vice President, and by the Secretary or an Assistant Secretary, or the Treasurer or an Assistant Treasurer, certifying the number of shares owned by him or her. Any or all of the signatures on the certificate may be by facsimile.

Section 2. Transfers of Stock.

Transfers of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents designated to transfer shares of the stock of the Corporation. Except where a certificate is issued in accordance with Section 4 of Article V of these Bylaws, an outstanding certificate, if one has been issued, for the number of shares involved shall be surrendered for cancellation before a new certificate, if any, is issued therefor.

Section 3. Record Date.

In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may, except as

 

8


otherwise required by law, fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions of this Section 3 at the adjourned meeting.

In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

In order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, (including electronic transmission as permitted by law), the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall be not more than ten days after the date upon which the resolution fixing the record date is adopted. If no record date has been fixed by the Board of Directors and no prior action by the Board of Directors is required by the Delaware General Corporation Law, the record date shall be the first date on which a consent setting forth the action taken or proposed to be taken is delivered to the Corporation in the manner prescribed by Article I, Section 9 hereof. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by the Delaware General Corporation Law with respect to the proposed action by consent of the stockholders without a meeting, the record date for determining stockholders entitled to consent to corporate action without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

Section 4. Lost, Stolen or Destroyed Certificates.

In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.

 

9


Section 5. Regulations.

The issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors may establish.

ARTICLE VI

NOTICES

Section 1. Notices.

If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the Delaware General Corporation Law.

Section 2. Waivers.

A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver.

ARTICLE VII

MISCELLANEOUS

Section 1. Facsimile Signatures.

In addition to the provisions for use of facsimile signatures elsewhere specifically authorized in these Bylaws, facsimile signatures of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors or a committee thereof.

Section 2. Books and Records.

Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be maintained on any information storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases); provided that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, the records so kept comply with Section 224 of the Delaware General Corporation Law. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to applicable law.

Section 3. Corporate Seal.

The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the Secretary. If and when so directed by the

 

10


Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.

Section 4. Reliance upon Books, Reports and Records.

Each director, each member of any committee designated by the Board of Directors, and each officer of the Corporation shall, in the performance of his or her duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees of the Board of Directors so designated, or by any other person as to matters which such director or committee member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

Section 5. Fiscal Year.

The fiscal year of the Corporation shall begin on January 1 and end on December 31 of each year.

Section 6. Checks, Notes, Drafts, Etc.

All checks, notes, drafts, or other orders for the payment of money of the Corporation shall be signed, endorsed, or accepted in the name of the Corporation by such officer, officers, person, or persons as from time to time may be designated by the Board of Directors or by an officer or officers authorized by the Board of Directors to make such designation.

Section 7. Dividends.

Subject to applicable law and the Certificate of Incorporation, dividends upon the shares of capital stock of the Corporation may be declared by the Board of Directors at any regular or special meeting of the Board of Directors. Dividends may be paid in cash, in property, or in shares of the Corporation’s capital stock, unless otherwise provided by applicable law or the Certificate of Incorporation

Section 8. Time Periods.

In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.

Section 9. Conflict with Applicable Law or Certificate of Incorporation.

These Bylaws are adopted subject to any applicable law and the Certificate of Incorporation. Whenever these Bylaws may conflict with any applicable law or the Certificate of Incorporation, such conflict shall be resolved in favor of such law or the Certificate of Incorporation.

 

11


ARTICLE VIII

INDEMNIFICATION OF DIRECTORS AND OFFICERS

Section 1. Actions, Suits and Proceedings Other than by or in the Right of the Corporation.

The Corporation shall indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the Corporation, or, while a director or officer of the Corporation, is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan) (all such persons being referred to hereafter as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974), and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.

Section 2. Actions or Suits by or in the Right of the Corporation.

The Corporation shall indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or officer of the Corporation, or, while a director or officer of the Corporation, is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including, without limitation, attorneys’ fees) actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, except that no indemnification shall be made under this Section 2 of Article VIII in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the

 

12


adjudication of such liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses (including, without limitation, attorneys’ fees) which the Court of Chancery of Delaware or such other court shall deem proper.

Section 3. Indemnification for Expenses of Successful Party.

Notwithstanding any other provisions of this Article VIII, to the extent that an Indemnitee has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Sections 1 and 2 of Article VIII, or in defense of any claim, issue or matter therein, or on appeal from any such action, suit or proceeding, Indemnitee shall be indemnified to the fullest extent permitted by law against all expenses (including, without limitation, attorneys’ fees) actually and reasonably incurred by or on behalf of Indemnitee in connection therewith.

Section 4. Notification and Defense of Claims.

As a condition precedent to an Indemnitee’s right to be indemnified, such Indemnitee must notify the Corporation in writing as soon as practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will or could be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is so notified, the Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own expense, with legal counsel reasonably acceptable to Indemnitee. After notice from the Corporation to Indemnitee of its election so to assume such defense, the Corporation shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee in connection with such action, suit, proceeding or investigation, other than as provided below in this Section 4 of Article VIII. Indemnitee shall have the right to employ his or her own counsel in connection with such action, suit, proceeding or investigation, but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless (a) the employment of counsel by Indemnitee has been authorized by the Corporation, (b) counsel to Indemnitee shall have reasonably concluded that there may be a conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct of the defense of such action, suit, proceeding or investigation or (c) the Corporation shall not in fact have employed counsel to assume the defense of such action, suit, proceeding or investigation, in each of which cases the fees and expenses of counsel for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this Article VIII. The Corporation shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Corporation or as to which counsel for Indemnitee shall have reasonably made the conclusion provided for in clause (b) above. The Corporation shall not be required to indemnify Indemnitee under this Article VIII for any amounts paid in settlement of any action, suit, proceeding or investigation effected without its written consent. The Corporation shall not settle any action, suit, proceeding or investigation in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee’s written consent. Neither the Corporation nor Indemnitee will unreasonably withhold or delay its consent to any proposed settlement.

 

13


Section 5. Advance of Expenses.

Subject to the provisions of Sections 4 and 6 of Article VIII, in the event of any threatened or pending action, suit, proceeding or investigation of which the Corporation receives notice under this Article VIII, any expenses (including, without limitation, attorneys’ fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding or investigation or any appeal therefrom shall be paid by the Corporation in advance of the final disposition of such matter to the fullest extent permitted by law; provided, however, that, to the extent required by law, the payment of such expenses incurred by or on behalf of Indemnitee in advance of the final disposition of such matter shall be made only upon receipt of an undertaking by or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Article VIII or otherwise; and provided further that no such advancement of expenses shall be made under this Article VIII if it is determined (in the manner described in Section 6 of Article VIII) that (a) Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Corporation, or (b) with respect to any criminal action or proceeding, Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such undertaking shall be accepted without reference to the financial ability of Indemnitee to make such repayment.

Section 6. Procedure for Indemnification and Advancement of Expenses.

In order to obtain indemnification or advancement of expenses pursuant to Section 1, 2, 3 or 5 of Article VIII, an Indemnitee shall submit to the Corporation a written request. Any such advancement of expenses shall be made promptly, and in any event within 60 days after receipt by the Corporation of the written request of Indemnitee, unless (a) the Corporation has assumed the defense pursuant to Section 4 of Article VIII (and none of the circumstances described in Section 4 of Article VIII that would nonetheless entitle the Indemnitee to indemnification for the fees and expenses of separate counsel have occurred) or (b) the Corporation determines within such 60-day period that Indemnitee did not meet the applicable standard of conduct set forth in Sections 1, 2 or 5 of Article VIII, as the case may be. Any such indemnification, unless ordered by a court, shall be made with respect to requests under Sections 1 or 2 of Article VIII only as authorized in the specific case upon a determination by the Corporation that the indemnification of Indemnitee is proper because Indemnitee has met the applicable standard of conduct set forth in Sections 1 or 2 of Article VIII, as the case may be. Such determination shall be made in each instance (a) by a majority vote of the directors of the Corporation consisting of persons who are not at that time parties to the action, suit or proceeding in question (“disinterested directors”), whether or not a quorum, (b) by a committee of disinterested directors designated by majority vote of disinterested directors, whether or not a quorum, (c) if there are no disinterested directors, or if the disinterested directors so direct, by independent legal counsel (who may, to the extent permitted by law, be regular legal counsel to the Corporation) in a written opinion or (d) by the stockholders of the Corporation.

Section 7. Remedies.

To the fullest extent permitted by law, the right to indemnification or advancement of expenses as granted by this Article VIII shall be enforceable by Indemnitee in any court of

 

14


competent jurisdiction. Neither the failure of the Corporation to have made a determination prior to the commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Corporation pursuant to Section 6 of Article VIII that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. In any suit brought by Indemnitee to enforce a right to indemnification or advancement, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VIII. Indemnitee’s expenses (including, without limitation, attorneys’ fees) reasonably incurred in connection with successfully establishing Indemnitee’s right to indemnification or advancement, in whole or in part, in any such proceeding shall also be indemnified by the Corporation to the fullest extent permitted by law. Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a right to indemnification hereunder it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the Delaware General Corporation Law.

Section 8. Limitations.

Notwithstanding anything to the contrary in this Article VIII, except as set forth in Section 7 of Article VIII, the Corporation shall not indemnify an Indemnitee pursuant to this Article VIII in connection with a proceeding (or part thereof) initiated by such Indemnitee unless the initiation thereof was approved by the Board of Directors. Notwithstanding anything to the contrary in this Article VIII, the Corporation shall not indemnify (or advance expenses to) an Indemnitee to the extent such Indemnitee is reimbursed (or advanced expenses) from the proceeds of insurance, and in the event the Corporation makes any indemnification (or advancement) payments to an Indemnitee and such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification (or advancement) payments to the Corporation to the extent of such insurance reimbursement.

Section 9. Subsequent Amendment.

No amendment, termination or repeal of this Article VIII or of the relevant provisions of the Delaware General Corporation Law or any other applicable laws shall adversely affect or diminish in any way the rights of any Indemnitee to indemnification or advancement of expenses under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal.

Section 10. Other Rights.

The indemnification and advancement of expenses provided by this Article VIII shall not be deemed exclusive of any other rights to which an Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory), agreement or vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee’s official capacity and as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to be a director or officer, and shall inure

 

15


to the benefit of the estate, heirs, executors and administrators of Indemnitee. Nothing contained in this Article VIII shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with officers and directors providing indemnification and advancement rights and procedures different from those set forth in this Article VIII. In addition, the Corporation may, to the extent authorized from time to time by the Board, grant indemnification and advancement rights to other employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article VIII.

Section 11. Partial Indemnification.

If an Indemnitee is entitled under any provision of this Article VIII to indemnification by the Corporation for some or a portion of the expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) or amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of such expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) or amounts paid in settlement to which Indemnitee is entitled.

Section 12. Insurance.

The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan) against any expense, liability or loss incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.

Section 13. Savings Clause.

If this Article VIII or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including, without limitation, an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article VIII that shall not have been invalidated and to the fullest extent permitted by applicable law.

 

16


Section 14. Definitions.

Terms used in this Article VIII and defined in Section 145(h) and Section 145(i) of the Delaware General Corporation Law shall have the respective meanings assigned to such terms in such Section 145(h) and Section 145(i).

ARTICLE IX

AMENDMENTS

These Bylaws may be adopted, amended or repealed by the Board of Directors or by the stockholders. In the case of any such amendment or repeal of Article VIII or any section thereof, the amendment or repeal shall be subject to Article VIII, Section 9.

 

17

EX-101.SCH 4 rxdx-20230616.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 rxdx-20230616_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 rxdx-20230616_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Jun. 16, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001718852
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Jun. 16, 2023
Entity Registrant Name PROMETHEUS BIOSCIENCES, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40187
Entity Tax Identification Number 81-4282653
Entity Address, Address Line One 3050 Science Park Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 422-4300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol RXDX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d466468d8k_htm.xml IDEA: XBRL DOCUMENT 0001718852 2023-06-16 2023-06-16 false 0001718852 --12-31 8-K 2023-06-16 PROMETHEUS BIOSCIENCES, INC. DE 001-40187 81-4282653 3050 Science Park Road San Diego CA 92121 (858) 422-4300 false false false false Common Stock, $0.0001 par value per share RXDX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d466468d8k.htm d466468dex31.htm d466468dex32.htm rxdx-20230616.xsd rxdx-20230616_lab.xml rxdx-20230616_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d466468d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d466468d8k.htm" ] }, "labelLink": { "local": [ "rxdx-20230616_lab.xml" ] }, "presentationLink": { "local": [ "rxdx-20230616_pre.xml" ] }, "schema": { "local": [ "rxdx-20230616.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rxdx", "nsuri": "http://prometheusbiosciences.com/20230616", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d466468d8k.htm", "contextRef": "duration_2023-06-16_to_2023-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d466468d8k.htm", "contextRef": "duration_2023-06-16_to_2023-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prometheusbiosciences.com//20230616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-168524-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-168524-xbrl.zip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end